Equities

Profile data is unavailable for this security.

About the company

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

  • Revenue in USD (TTM)22.32bn
  • Net income in USD5.90bn
  • Incorporated1987
  • Employees11.00k
  • Location
    Gilead Sciences Inc333 LAKESIDE DRFOSTER CITY 94404United StatesUSA
  • Phone+1 (650) 574-3000
  • Fax+1 (650) 578-9264
  • Websitehttp://www.gilead.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Vertex Pharmaceuticals Incorporated3.27bn594.86m43.22bn2.50k73.789.1666.3213.242.298.2912.5718.430.62223.418.531,306,093.0010.83-5.1113.32-6.6586.7488.1817.41-8.993.6640.520.1061--22.4620.25103.80--13.20--
Biogen Inc13.81bn4.69bn44.46bn7.80k9.833.247.623.2223.3323.2168.5170.850.52582.375.411,770,718.0018.1418.8020.6021.9285.7287.2734.4932.272.60--0.30070.009.6114.1819.9819.05-24.06--
Allergan plc15.71bn-7.23bn45.96bn16.90k--0.7468--2.92-21.63-21.5946.72187.740.14962.295.85929,727.80-6.88-3.61-7.40-3.8986.2283.23-45.98-28.240.60410.65080.2765---0.961743.4124.17---3.81--
Zoetis Inc5.91bn1.35bn48.81bn10.00k36.7921.0828.908.252.772.8612.194.840.60431.406.18591,400.0013.7210.6515.3712.7566.9366.0522.7116.422.798.990.735523.639.765.0128.5322.3712.9320.91
Celgene Corporation15.77bn4.75bn67.30bn8.85k14.518.2412.444.276.586.5821.8511.580.43681.217.301,781,292.0013.1410.9114.5712.1696.2595.9430.0924.552.666.580.7130.0017.5218.67-3.8722.7818.86--
Bristol-Myers Squibb Co23.29bn5.17bn76.63bn23.30k14.845.0412.943.293.163.1414.239.300.68585.355.19999,485.0015.2910.0521.0813.9271.1373.8722.2917.901.7928.850.28274.948.596.6127.4914.1912.112.71
Gilead Sciences, Inc.22.32bn5.90bn84.38bn11.00k14.623.8511.523.784.544.5417.2017.230.34825.396.322,029,091.009.1923.0810.9228.2278.4584.3726.4043.523.5310.790.546117.01-15.2414.59-46.0612.1737.10--
Amgen, Inc.23.75bn8.08bn103.63bn21.50k13.569.6410.324.3612.5312.5336.8817.630.35141.416.421,104,651.0011.959.9614.4211.4282.2781.1534.0032.602.5313.020.75340.323.934.923.9010.561.2722.94
Eli Lilly And Co23.95bn2.75bn112.63bn38.68k42.7945.4126.254.702.716.2823.582.550.58151.564.95619,128.806.686.489.269.0074.9674.0111.4911.690.849329.720.861687.087.361.2299.27-6.1722.522.80
AbbVie Inc32.65bn5.42bn117.47bn30.00k22.47--16.153.603.543.4821.58-5.290.51784.315.671,088,233.008.649.3011.4512.1277.3177.2416.6818.820.91425.261.2783.7616.0811.751.066.835.3817.54
Data as of May 17 2019. Currency figures normalised to Gilead Sciences Inc's reporting currency: US Dollar USD

Institutional shareholders

31.13%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 201999.51m7.81%
Capital Research & Management Co. (Global Investors)as of 31 Mar 201978.19m6.13%
BlackRock Fund Advisorsas of 31 Mar 201966.45m5.21%
SSgA Funds Management, Inc.as of 31 Mar 201958.65m4.60%
Geode Capital Management LLCas of 31 Mar 201917.62m1.38%
Dodge & Coxas of 31 Mar 201917.07m1.34%
Northern Trust Investments, Inc.as of 31 Mar 201916.84m1.32%
Capital Research & Management Co. (World Investors)as of 31 Mar 201916.24m1.27%
Invesco Capital Management LLCas of 31 Mar 201913.25m1.04%
Parnassus Investmentsas of 31 Mar 201913.07m1.03%
More ▼
Data from 31 Mar 2019 - 31 Mar 2019Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.